Healthcare & Life Sciences Insights

Discover Latham’s latest insights into the commercial, regulatory, and legal developments shaping the global healthcare and life sciences landscape.

Latham’s cross-disciplinary team delivers insightful, practical guidance and sophisticated representation to a full spectrum of healthcare and life sciences companies across the globe, on every type of transaction or dispute a company may face.

Learn more about our capabilities

In the Spotlight

Healthcare & Life Sciences Market Update

Shiny transparent capsule filled with colorful spheres

June 21, 2024 Podcast

Episode 82 — Drug Pricing: Takeaways From the New Orleans Pricing and Contracting USA Conference

Close up of Asian women with hi tech digital technology screen over the eye.

May 30, 2024 Webcast

US Regulators’ Joint Inquiry Into Healthcare Consolidation: Navigating the New Landscape

April 30, 2024 Client Alert

US Regulators Announce Inquiry Into Healthcare Consolidation

January 4, 2024 Article

2024 Drug Pricing Look Ahead: Federal, State Drug Pricing Plans Likely to Prompt Challenges

March 15, 2024 Article

Recent Updates on Emerging Trends in the Global Regulation of Digital Health

In the latest edition of ICLG Digital Health 2024, partners Eveline Van Keymeulen and Elizabeth Richards, counsel Nicole Liffrig Molife, and associate Oliver Mobasser discuss emerging trends in the global regulation of digital health in the US, EU, and UK, and the frameworks striving to catch up with technological advancement.

November 13, 2023 Article

Clinical Trials: Overview (France)

A practice note providing an overview of the regulation of clinical trials of medicinal products in France.

November 2, 2023 Client Alert

President Biden’s Executive Order on Artificial Intelligence — Initial Analysis of Private Sector Implications

July 18, 2024 Article

“Should I Sue?”: Navigating the New APA Landscape With Latham’s Phil Perry and Andrew Prins

June 21, 2024 Podcast

Episode 82 — Drug Pricing: Takeaways From the New Orleans Pricing and Contracting USA Conference

June 13, 2024

Episode 81 — Drug Pricing: A Look Behind the Curtain of the New ASP Reporting Website and Other Data Collection Portals

The new ASP reporting website highlights the increasing significance of data collection portals — and yet the number of permitted users is very small. Join us as we learn from leading practitioners at Riparian how to navigate the complex web of compliance requirements.

June 21, 2024

Episode 82 — Drug Pricing: Takeaways From the New Orleans Pricing and Contracting USA Conference

One of the year’s major drug pricing conferences just concluded in New Orleans. Join the Latham team to discuss takeaways from the conference, with topics including 340B developments, state legislative activity, and IRA implementation.

May 30, 2024

US Regulators’ Joint Inquiry Into Healthcare Consolidation: Navigating the New Landscape

Latham’s healthcare enforcement and antitrust practitioners discuss how companies can navigate the complexities of healthcare consolidation and regulatory compliance. MCLE credit offered.

March 06, 2024

Next Generation of Nicotine: Center for Tobacco Products — 2024 Outlook

Latham’s FDA Regulatory lawyers discuss CTP’s 2024 agenda for tobacco and nicotine products. MCLE credit offered.

February 21, 2024

2024 FDA Outlook: Healthcare & Life Sciences

Latham’s Healthcare & Life Sciences lawyers discuss FDA’s regulatory and legislative agenda for 2024. MCLE credit offered.

February 01, 2024

Episode 71 — Drug Pricing: A Look Ahead at Trends for 2024

Listen to this “lightning round” to hear how the policy and regulatory environment will likely remain hostile for pharmaceutical manufacturers, and how to address the turbulence that lies ahead.

January 25, 2024

Episode 68 — Drug Pricing: Will Agencies Exercise March-In Rights Based on Drug Price?

A new proposal seeks to reinvigorate the Bayh-Dole Act by allowing government to consider price as a factor when electing to exercise march-in rights.

December 13, 2023

Episode 62 — Has FDA Meaningfully Changed Its Restrictions on Off-Label Communications?

New draft guidance document signals an expanded safe harbor for communicating scientific information on unapproved uses of approved medical products.

Episode 61 Drug Pricing New OIG Guidance Reaffirms the Seven Elements of Effective Compliance

December 08, 2023

Episode 61 — Drug Pricing: New OIG Guidance Reaffirms the Seven Elements of an Effective Compliance Program

Hear from Latham attorneys and a leading industry practitioner what the OIG compliance guidance means for drug manufacturers.

December 05, 2023

Common Pitfalls in Structuring Non-Dilutive Financings Using Licenses or Collaborations

Latham Healthcare & Life Sciences partners discuss alternative financing through strategic licensing and partnerships as part of the Jefferies London Healthcare Conference.

October 20, 2023

Episode 57 — Drug Pricing: What Trends Emerged From the 2023 Medicaid Drug Rebate Program Summit?

Industry stakeholders shone a light on recent agency actions as the Inflation Reduction Act’s drug price negotiations proceed.

Our Archive

Close-up of an array of test tubes in a laboratory

July 26, 2024 Our Work

Latham Advises Lenders on Financing for Ardian’s Acquisition of Majority Stake in Masco Group

A cross-border team represented the lenders in the transaction to acquire a majority stake in a leading solution provider to the biopharma and life sciences industry.

Close-up of stethoscope on desk with doctor's hands using laptop. The female doctor is sitting at desk in office. The focus is on stethoscope.

July 25, 2024 Our Work

Latham & Watkins Advises on Concentra IPO

Capital markets team represents the underwriters in the offering by the provider of occupational health services.

July 25, 2024 Our Work

Latham Advises on Financing for Cosette Pharmaceuticals

July 24, 2024 Our Work

Latham & Watkins Advises on Kestra Medical Technologies’ US$196 Million Financing Round

July 19, 2024 Our Work

Latham Advises Health Catalyst in Secured Growth Financing

June 7, 2024 Recognition

Litigator of the Week Runners-Up and Shout Outs — SCAN Health Plan

Latham litigators won an Administrative Procedure Act case on behalf of SCAN Health Plan over a new plan rating methodology which would have cost them US$250 million in federal funding.

June 6, 2024 Recognition

Latham Leads the Rankings in Chambers USA 2024 Guide

Firm received the most practice and individual rankings for the tenth consecutive year.

Blurry vision of the sun reflected in the glass skyscraper.

May 28, 2024 Recognition

Litigator of the Week Runners-Up and Shout Outs — Funko and United Therapeutics

Latham lawyers honored for securing the dismissal of a securities fraud complaint brought against Funko and its former CEO and CFO, and for a win at the D.C. Circuit for United Therapeutics.

Artificial Intelligence Capital Markets European Union Life Sciences Regulatory FDA Regulatory Healthcare & Life Sciences Healthcare Regulatory Intellectual Property Litigation Life Sciences Licensing Litigation & Trial Mergers & Acquisitions Private Equity Public Company Representation Securities Litigation & Professional Liability Technology

The Book of Jargon® Series

Book of Jargon Healthcare & Life Sciences

Download the App

Hyperkalemia

The Book of Jargon® – Healthcare & Life Sciences

a medical term used to describe a potassium level in a patient’s blood that is higher than normal.

Word of the Day®

Overpayment

The Book of Jargon® – Healthcare & Life Sciences

amounts that a person or entity receives or retains to which the person is not entitled. The ACA requires Medicare and Medicaid Providers, Suppliers, and other entities to report and return any overpayment of Medicare or Medicaid funds within 60 days of identifying the overpayment or face potential False Claims Act liability.

Word of the Day®

Sequestration

The Book of Jargon® – Healthcare & Life Sciences

automatic, across the board budget cuts in the amount of US$1.2 trillion over nine years enacted as part of the Budget Control Act of 2011 that took effect in 2013 when Congress could not agree on a plan to reduce the deficit. Sequestration included aggregate reductions of Medicare payments to Providers at 2% per fiscal year.

Word of the Day®

Yates Memo

The Book of Jargon® – Healthcare & Life Sciences

named after author Deputy Attorney General Sally Yates, the memo formally titled “Individual Accountability for Corporate Wrongdoing” emphasized the Department of Justice’s focus on holding individual corporate executives accountable for corporate wrongdoing. The memo set forth six steps to reinforce the Department of Justice’s pursuit of individual wrongdoing.

Word of the Day®

Rational Drug Design

The Book of Jargon® – Healthcare & Life Sciences

the process of discovering new Drugs based on knowledge of a Biological Target. Generally, a Molecule associated with a disease is identified and assessed, then a drug Molecule is designed to inhibit or promote certain reactions in an organism to respond to the disease.

Word of the Day®